Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Apr 7;13:847008. doi: 10.3389/fimmu.2022.847008

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2022 Soldierer, Bister, Haist, Thivakaran, Cengiz, Sendker, Bartels, Thomitzek, Smorra, Hejazi, Uhrberg, Scheckenbach, Monzel, Wiek, Reinhardt, Niktoreh and Hanenberg

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Cytotoxic activity of CAR NK cells against leukemic cells. (A) AML cells NOMO-1 and MOLM-14, and ALL cells REH were analyzed for their surface expression of CD19, CD33, and CD123. (C) Primary pediatric M4 and M5 AML blasts were analyzed for their surface expression of CD33, CD123, and EGFR using conjugated antibodies by flow cytometry. CAR-transduced and microbead-enriched primary human NK cells were blocked as described previously and co-cultured with NOMO-1, MOLM-14, and REH cells (B) or primary pediatric M4 and M5 AML blasts (D) at various effector-to-target cell ratios to determine the specific cytotoxic activity of CAR NK cells. The graphs represent mean ± SEM of at least five (cell lines) or three (AML blasts) biological replicates.